No Data
No Data
Increased support for innovative drugs, the collective rise of the innovative drug sector, sino biopharm (01177) rose 4.5%.
Jingu Finance News | The innovative drug sector as a whole is on the rise, with Lai Kai Medicine (02105) up 6.07%, Sino Biopharm (01177) up 4.5%, Genscript Bio (01548) up 4.07%, Hutchmed (China) (00013) up 2.68%, and Innovent Bio (01801) up 2.1%. The State Council Information Office held a series of themed press conferences on 'Promoting High-Quality Development', and Li Li, Director of the National Medical Products Administration, stated at the conference the increased support for pharmaceutical R&D innovation. This includes the evaluation and approval, inspection and verification of innovative drugs and medical instruments that are key to the country's support.
Lai Kai Pharmaceuticals-B (02105.HK) has granted a total of 11.24 million restricted share units to the grantee.
On September 5, 2024, Lai Kai Medicine-B (02105.HK) announced that it will grant a total of 11.24 million restricted share units (equivalent to a total of 11.24 million shares) under the 2024 share incentive plan to the grantee (including three executive directors). The grant of restricted share units to the three executive directors, including Lv Xiangyang, Xie Ling, and Gu Xiangju, must be approved by independent shareholders at a special general meeting of shareholders before it can take effect.
LAEKNA-B: Interim Report 2024
Hong Kong stocks surged | Lai Kai Medicine-B (02105) rose more than 12%, research and development expenses of the company in the first half of the year increased year-on-year, and the progress of new drug research and development is smooth.
Lai Kai Pharmaceuticals-B(02105) rose by more than 12%, as of the time of publication, up 12.13%, to HK$5.64, with a turnover of HK$10.0499 million.
HK stocks volatility | Lai Kai Pharmaceutical-B (02105) rose more than 6%. The company's financial situation is robust and the clinical trial progress exceeds expectations.
Lai Kai Medicine-B (02105) rose over 6%, as of press time, up 6.48% to HKD 4.93, with a turnover of 3.894 million Hong Kong dollars.
The most coveted biotech for the next generation of drug kings.
On August 19th, Lai Kai Pharmaceutical - B (02105) released its H1 2024 performance report and held a mid-term performance briefing. The company implemented the strategy of efficient capital utilization and focusing on core pipeline, and currently has enough cash and deposit balances to support the company's operation for the next two years.
No Data
No Data